Advertisement
Canada markets open in 7 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7320
    -0.0003 (-0.04%)
     
  • CRUDE OIL

    84.36
    +0.79 (+0.95%)
     
  • Bitcoin CAD

    87,171.29
    +1,372.12 (+1.60%)
     
  • CMC Crypto 200

    1,385.44
    -11.09 (-0.79%)
     
  • GOLD FUTURES

    2,361.50
    +19.00 (+0.81%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.6630
    -0.0430 (-0.91%)
     
  • NASDAQ futures

    17,708.25
    +140.75 (+0.80%)
     
  • VOLATILITY

    15.42
    +0.05 (+0.33%)
     
  • FTSE

    8,116.92
    +38.06 (+0.47%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Stocks in play: ProMIS Neurosciences, Inc.

Announced today an outline of its strategic priorities and action plan for 2021. The priorities for 2021 fall into four key areas: Near-term focus on rare neurodegenerative diseases, especially ALS; Use of proprietary platform to support portfolio expansion; PMN310 antibody lead program for Alzheimer’s disease; COVID-19, further progress on serological assays. ProMIS Neurosciences, Inc. shares T.PMN are trading unchanged at $0.10.

Read: